Form 4: Quest Diagnostics Executive Acquires Shares and Stock Options

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports acquisition of common stock and stock options.

Summary

• On February 12, 2025, Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reported a transaction involving the company's securities.
• Delaney acquired 1,815 shares of common stock.
• Delaney also acquired 6,960 non-qualified stock options with an exercise price of $165.30, vesting in three equal annual installments beginning on February 12, 2026, and expiring on February 12, 2035.
• Following the reported transactions, Delaney beneficially owns 6,439 shares of common stock and 6,960 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The acquisition of shares and options could be seen as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of shares and stock options by a high-ranking executive could be interpreted as a sign of confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Insider trading activity is a common metric followed across the industry.
• Comparing Delaney's transactions to those of executives at comparable companies like Laboratory Corporation of America (LH) or Bio-Reference Laboratories can provide context.
• The size and frequency of these transactions are generally compared against industry averages to assess their significance.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.
• There is no immediate impact on employees, customers, suppliers, or creditors.

Key Dates